Precigen (PGEN) Depreciation & Amortization (CF) (2012 - 2026)
Precigen (PGEN) reported Depreciation & Amortization (CF) of $1.1 million for Q1 2026, up 74.72% year-over-year from $629000.0 in Q1 2025, and down 3.34% quarter-over-quarter from $1.1 million in Q4 2025.
Precigen (PGEN) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $1.1 million in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $1.1 million, up 74.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 3.06% YoY), and the FY2025 annual result was $3.2 million, down 29.32% from the prior year.
- Depreciation & Amortization (CF) retreated to $1.1 million in Q1 2026 per PGEN's latest filing, from $1.1 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $3.3 million in Q1 2022 and troughed at $629000.0 in Q1 2025.
- A 5-year average of $1.4 million and a median of $1.6 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) sank 60.56% in 2025, then surged 74.72% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.7 million in 2022, then declined by 6.22% to $1.6 million in 2023, then slumped by 59.05% to $661000.0 in 2024, then surged by 72.01% to $1.1 million in 2025, then decreased by 3.34% to $1.1 million in 2026.
- Business Quant data shows PGEN's Depreciation & Amortization (CF) at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $803000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 429,663.65 |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 803,000.00 |
| Sep 30, 2025 | 803,000.00 |
| Jun 30, 2025 | 630,000.00 |
| Jun 30, 2025 | 630,000.00 |
| Mar 31, 2025 | 629,000.00 |
| Mar 31, 2025 | 629,000.00 |
| Dec 31, 2024 | 661,000.00 |
| Dec 31, 2024 | 661,000.00 |
| Sep 30, 2024 | 674,000.00 |
| Sep 30, 2024 | 674,000.00 |
| Jun 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.60 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Dec 31, 2023 | 1.61 Mn |